Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CCND3
REST API REST API
Homo sapiens
CCND3 is differentially expressed in 300 experiments: 105 organism parts: thymus, bone marrow, ... (103 more);, 217 disease states: normal, acute lymphoblastic leukemia, ... (215 more);, 95 cell types 428 cell lines 39 compound treatments and 74 other conditions.
Orthologs Ccnd3 (Mus musculus)   Q5ZKI9_CHICK (Gallus gallus)   F1MV86_BOVIN (Bos taurus)   F6S8K9_CIOIN (Ciona intestinalis)   CycD (Drosophila melanogaster)   CCND3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cyclin-dependent protein kinase activity, cell division, protein binding, cytoplasm, membrane, regulation of cyclin-dependent protein kinase activity, cell cycle, regulation of cell cycle, protein kinase binding, nucleus, signal transduction, T cell proliferation, positive regulation of cyclin-dependent protein kinase activity, cyclin-dependent protein kinase holoenzyme complex, protein phosphorylation, positive regulation of protein phosphorylation
InterPro Term Cyclin-like, Cyclin_N, Cyclin_C, Cyclin_A/B/D/E
UniProt Accession P30281, D6RDF8, D6RDL3, D6RIX2, D6RI00, Q5T8J1, B3KQ22, E9PB36, E9PAS4
Search EB-eye ENSG00000112576
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-GEOD-18105, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-18005, E-GEOD-19397, E-GEOD-4717, ... (40 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-62, E-MTAB-37, E-MEXP-440
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
MDA468
2
E-MEXP-440, E-MTAB-62
A549
2
E-GEOD-3202, E-GEOD-6013
BT20
2
E-MTAB-37, E-MTAB-62
Jurkat
2
E-GEOD-1880, E-MTAB-62
422 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, ... (51 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-3204, E-GEOD-3920
whole blood
2
E-GEOD-3026, E-MTAB-25
germ cell
1
E-MTAB-25
purified CLL B cells from peripheral blood
1
E-GEOD-22529
CD11c+ dendritic cell
1
E-MEXP-1600
neutrophil
1
E-GEOD-12662
89 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-GEOD-3678, ... (53 experiments)

Factor Value U/D Experiments
chronic lymphocytic leukemia
2
E-GEOD-2466, E-GEOD-6691
Burkitt's lymphoma
2
2
E-MTAB-37, E-GEOD-1880
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
colorectal adenocarcinoma
2
E-AFMX-5, E-MTAB-37
control
2
E-GEOD-21912, E-GEOD-20602
dermatomyositis
2
E-MTAB-62, E-GEOD-1551
211 more value(s).


Compound treatment

studied in E-GEOD-7400, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-MEXP-1958, ... (26 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
eicosapentaenoic acid
1
E-MEXP-1389
all-trans retinoic acid
1
E-GEOD-995
2,3-dimethoxy-1,4-naphthoquinone
1
E-GEOD-6907
nickel(II) chloride hexahydrate
1
E-GEOD-6907
ZMYM2/FGFR1
1
E-GEOD-15811
33 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1140, E-MEXP-1251, E-GEOD-21374, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-MEXP-2359, E-GEOD-2666, E-MTAB-62

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-TABM-147, E-GEOD-21887, E-GEOD-19665, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-MEXP-421, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-TABM-440, E-GEOD-837, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-GEOD-426

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phenotype
studied in E-GEOD-22152, E-GEOD-22309, E-GEOD-21750, E-MEXP-1403

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19246

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, E-MEXP-548, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-GEOD-1926

Tissue
studied in E-GEOD-30573

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-19246, E-GEOD-19136, E-GEOD-19815, ... (7 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Processing time: 0.244 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM